MHMartin Hjorth

Martin Hjorth

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Martin Hjorth has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Legionnaires’ disease from a cooling tower in a community outbreak in Lidköping, Sweden- epidemiological, environmental and microbiological investigation supported by meteorological modelling

    by Peter Ulleryd, Anna Hugosson, Görel Allestam, Sverker Bernander, Berndt Eb Claesson, Ingrid Eilertz, Anne-Christine Hagaeus, Martin Hjorth, Agneta Johansson, Birgitta de Jong, et al.

    An outbreak of Legionnaires’ Disease took place in the Swedish town Lidköping on Lake Vänern in August 2004 and the number of pneumonia cases at the local hospital increased markedly. As soon as the first patients were diagnosed, health care providers were informed and an outbreak investigation was launched.


  • Open Access

    Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study

    by Martin Hjorth, Øyvind Hjertner, Lene Meldgaard Knudsen, Nina Gulbrandsen, Erik Holmberg, Per Trøllund Pedersen, Niels Frost Andersen, Björn Andréasson, Rolf Billström, Kristina Carlson, et al.

    Objectives:  Thalidomide and bortezomib have been frequently used for second‐line therapy in patients with myeloma relapsing after or refractory to initial melphalan‐based treatment, but no randomized trials have been published comparing these two treatment alternatives.Methods:  Thalidomide‐ and bortezomib‐naïve patients with melphalan refractory myeloma were randomly assigned to low‐dose thalidomide + dexamethasone (Thal‐Dex) or bortezomib + dexamethasone (Bort‐Dex). At progression on either therapy, the patients were offered crossover to the alternative drug combination. An estimated 300 patients would be needed for the trial to detect a 50% difference in median PFS between the treatment arms.Results:  After inclusion of 131 patients, the trial was prematurely closed because of low accrual. Sixty‐seven patients were randomized to Thal‐Dex and 64 to Bort‐Dex. Progression‐free survival was similar (median, 9.0 months for Thal‐Dex and 7.2 for Bort‐Dex). Response rate was similar (55% for Thal‐Dex and 63% for Bort‐Dex), but time to response was shorter (P < 0.05) and the VGPR rate higher (P < 0.01) for Bort‐Dex. Time‐to‐other treatment after crossover was similar (median, 13.2 months for Thal‐Dex and 11.2 months for Bort‐Dex), as was overall survival (22.8 months for Thal‐Dex and 19.0 for Bort‐Dex). Venous thromboembolism was seen in seven patients and cerebrovascular events in four patients in the Thal‐Dex group. Severe neuropathy, reactivation of herpes virus infections, and mental depression were more frequently observed in the Bort‐Dex group. In the quality‐of‐life analysis, no difference was noted for physical function, pain, and global quality of life. Fatigue and sleep disturbances were significantly more prevalent in the Bort‐Dex group.Conclusions:  Thalidomide (50–100 mg daily) in combination with dexamethasone seems to have an efficacy comparable with that of bortezomib and dexamethasone in melphalan refractory myeloma. However, the statistical strength of the results in this study is limited by the low number of included patients.


  • Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation

    by Cecilie Blimark, Ljupco Veskovski, Jan Westin, Stig Rödjer, Mats Brune, Martin Hjorth, Erik Holmberg, Per-Ola Andersson, Ulf-Henrik Mellqvist

    Today, a number of therapeutic options are available as the patient with myeloma relapses from initial treatment with high-dose melphalan and autologous stem cell transplantation (ASCT). For patients who experience a durable response to primary ASCT, retreatment with high-dose melphalan is recommended by many current guidelines. Yet, toxicity is an important aspect in the choice of relapse treatment, and a second ASCT in this setting could be associated with enhanced toxicity. As the goal for the treatment for relapsed myeloma should be disease control while maintaining quality of life, lower doses of melphalan might be preferable. In this retrospective study, we account for the outcome of 66 patients with myeloma in first systemic relapse after ASCT, who were treated with intermediate-dose melphalan, 100 mg/m2, and stem cell support (MEL 100). The aim was to evaluate this treatment in relation to prior response duration after initial ASCT and with respect to response rate, toxicity and survival. The overall response rate was 62%. There was limited, mostly haematological, toxicity, and no treatment-related mortality was observed. The median progression-free survival (PFS) was 8.5 months, and the median overall survival was 24 months. Patients with time to progression of 34 months or more (n=17; ≥75th percentile) after initial ASCT had a median PFS of 12.5 months after MEL 100. For patients with a long-lasting response after ASCT, MEL 100 could be a therapeutic option with low toxicity and with efficacy comparable to newer immunomodulatory drugs.


    • 1 September 2006
      • Vol. 91  (9) , 1228-33

    Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation.

    by Stig Lenhoff, Martin Hjorth, Ingemar Turesson, Jan Westin, Peter Gimsing, Finn Wislöff, Lucia Ahlberg, Kristina Carlson, Ilse Christiansen, Inger Marie Dahl, et al.

    From 1994 to 1997 we conducted a population-based, prospective study on intensive therapy in newly diagnosed symptomatic myeloma patients younger than 60 years, comparing their survival to that of a conventionally treated historic population. Long-term results are presented, including the impact of the degree of response on survival and relapse pattern after transplantation. The prospective population was formed of 397 patients and the historic population of 313 patients. Both populations were calculated to comprise more than 75% of the expected number of new cases. After a median follow-up of 7 years survival was longer in the prospective population than in the historic one (median 60 versus 39 months; p=0.0002). When comparing only patients eligible for intensive therapy the median survival was 63 versus 44 months (p<0.0001). Attaining a complete response was associated with prolonged event-free survival but not overall survival. The pattern of relapse after transplantation was heterogeneous but could be divided into four major groups; insidious, classical, plasmacytoma form and transformed disease. The median survival after relapse was 29 months. The relapse pattern and time to relapse predicted outcome. Patients relapsing with an insidious or classical form of disease with skeletal events only, or after a long lasting first response were likely to respond well to conventional salvage therapy. In contrast, relapse with multiple symptoms, transformed disease or a short duration of first response implied bad prognosis. The relapse pattern after autologous transplantation is heterogeneous and response to salvage therapy is variable. The degree of response and event-free survival after transplantation are not reliable surrogate markers for survival.


  • Impact of age on survival after intensive therapy for multiple myeloma: a population‐based study by the Nordic Myeloma Study Group

    by Stig Lenhoff, Martin Hjorth, Jan Westin, Lorentz Brinch, Bengt Bäckström, Kristina Carlson, Ilse Christiansen, Inger Marie Dahl, Peter Gimsing, Jens Hammerström, et al.

    The value of intensive therapy, including autologous stem cell transplantation, in newly diagnosed myeloma patients >60 years is not clear. We evaluated the impact of age (<60 years vs. 60-64 years) on survival in a prospective, population-based setting and compared survival with conventionally treated historic controls. The prospective population comprised 452 patients registered between 1998 and 2000. Of these, 414 received intensive therapy. The historic population, derived from our most recent population-based study on conventional therapy, comprised 281 patients. Of these, 243 fulfilled our eligibility criteria for intensive therapy. For patients undergoing intensive therapy it was found that two factors, beta-2-microglobulin and age <60 years vs. 60-64 years, had independent prognostic impact on survival. However, compared with the historic controls a survival advantage was found both for patients <60 (median 66 months vs. 43 months, P < 0.001) and 60-64 years (median 50 months vs. 27 months; P = 0.001). We conclude that in a population-based setting higher age adversely influences outcome after intensive therapy. Our results indicate that intensive therapy prolongs survival also at age 60-64 years but with less superiority than in younger patients.